DOCSLIB.ORG

Supplemental Digital Content

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Digital Content SUPPLEMENTAL DIGITAL CONTENT Drug Name Active Ingredients ACCURETIC HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE ALDACTAZIDE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE ALDORIL 15 HYDROCHLOROTHIAZIDE; METHYLDOPA ALDORIL 25 HYDROCHLOROTHIAZIDE; METHYLDOPA ALDORIL D30 HYDROCHLOROTHIAZIDE; METHYLDOPA ALDORIL D50 HYDROCHLOROTHIAZIDE; METHYLDOPA AMILORIDE HYDROCHLORIDE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE AMLODIPINE BESYLATE, VALSARTAN AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; AND HYDROCHLOROTHIAZIDE VALSARTAN AMTURNIDE ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE;HYDROCHLOROTHIAZIDE APRESAZIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE APRESOLINE-ESIDRIX HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE ATACAND HCT CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE AVALIDE HYDROCHLOROTHIAZIDE; IRBESARTAN BENAZEPRIL HYDROCHLORIDE BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE BENICAR HCT HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL BISOPROLOL FUMARATE BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE CAM-AP-ES HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE CANDESARTAN CILEXETIL CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE CANDESARTAN CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE CILEXETIL; HYDROCHLOROTHIAZIDE CAPOZIDE 25/15 CAPTOPRIL; HYDROCHLOROTHIAZIDE CAPOZIDE 25/25 CAPTOPRIL; HYDROCHLOROTHIAZIDE CAPOZIDE 50/15 CAPTOPRIL; HYDROCHLOROTHIAZIDE CAPOZIDE 50/25 CAPTOPRIL; HYDROCHLOROTHIAZIDE CAPTOPRIL AND HYDROCHLOROTHIAZIDE CAPTOPRIL; HYDROCHLOROTHIAZIDE DIOVAN HCT HYDROCHLOROTHIAZIDE; VALSARTAN DUTOPROL HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE DYAZIDE HYDROCHLOROTHIAZIDE; TRIAMTERENE ENALAPRIL MALEATE ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE ESIDRIX HYDROCHLOROTHIAZIDE ESIMIL GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE EXFORGE HCT AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN FOSINOPRIL SODIUM FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE H.R.-50 HYDROCHLOROTHIAZIDE; RESERPINE HYDRA-ZIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE HYDRALAZINE AND HYDROCHLORTHIAZIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE AND HYDROCHLOROTHIAZIDE HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE W/ HYDROCHLOROTHIAZIDE 100/50 HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE W/ HYDROCHLOROTHIAZIDE 25/25 HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE W/ HYDROCHLOROTHIAZIDE 50/50 HYDRALAZINE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE RESERPINE HYDRALAZINE HYDROCHLORIDE- HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE-RESERPINE RESERPINE HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE RESERPINE HYDRAP-ES HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE HYDRO-D HYDROCHLOROTHIAZIDE HYDRO-RESERP HYDROCHLOROTHIAZIDE; RESERPINE HYDRO-RIDE AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE HYDRO-SERP ""25"" HYDROCHLOROTHIAZIDE; RESERPINE HYDRO-SERP ""50"" HYDROCHLOROTHIAZIDE; RESERPINE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE INTENSOL HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE W/ HYDRALAZINE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE W/ RESERPINE HYDROCHLOROTHIAZIDE; RESERPINE HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; HYDRALAZINE RESERPINE HYDROCHLOROTHIAZIDE; IRBESARTAN HYDROCHLOROTHIAZIDE; IRBESARTAN HYDRODIURIL HYDROCHLOROTHIAZIDE HYDROPRES 25 HYDROCHLOROTHIAZIDE; RESERPINE HYDROPRES 50 HYDROCHLOROTHIAZIDE; RESERPINE HYDROSERPINE PLUS (R-H-H) HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE HYZAAR HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM INDERIDE LA 120/50 HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE INDERIDE LA 160/50 HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE INDERIDE LA 80/50 HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE INDERIDE-40/25 HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE INDERIDE-80/25 HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE IRBESARTAN AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; IRBESARTAN IRBESARTAN AND HYDROCHLOROTHIAZIDE IRBESARTAN AND HYDROCHLOROTHIAZIDE IRBESARTAN HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; IRBESARTAN IRBESARTAN; HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; IRBESARTAN IRBESARTAN; HYDROCHLOROTHIAZIDE IRBESARTAN: HYDROCHLOROTHIAZIDE IRBESARTAN; HYDROCHLOROTHIAZIDE IRBESARTAN; HYDROCHLOROTHIAZIDE LISINOPRIL AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; LISINOPRIL LOPRESSOR HCT HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE LOTENSIN HCT BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE MAXZIDE HYDROCHLOROTHIAZIDE; TRIAMTERENE MAXZIDE-25 HYDROCHLOROTHIAZIDE; TRIAMTERENE METHYLDOPA AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; METHYLDOPA METOPROLOL TARTRATE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE MICARDIS HCT HYDROCHLOROTHIAZIDE; TELMISARTAN MICROZIDE HYDROCHLOROTHIAZIDE MODURETIC 5-50 AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE MOEXIPRIL HYDROCHLORIDE HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE HYDROCHOLROTHIAZIDE MONOPRIL-HCT FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE NORMOZIDE HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE OLMESARTAN OLMESARTAN MEDOXOMIL; HYDROCHLOROTHIAZIDE MEDOXOMIL; HYDROCHLOROTHIAZIDE ORETIC HYDROCHLOROTHIAZIDE ORETICYL 25 DESERPIDINE; HYDROCHLOROTHIAZIDE ORETICYL 50 DESERPIDINE; HYDROCHLOROTHIAZIDE ORETICYL FORTE DESERPIDINE; HYDROCHLOROTHIAZIDE PRINZIDE HYDROCHLOROTHIAZIDE; LISINOPRIL PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE PROPRANOLOL HYDROCHLORIDE HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE QUINAPRIL HYDROCHLORIDE HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE QUINARETIC HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE RESERPINE AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; RESERPINE RESERPINE AND HYDROCHLOROTHIAZIDE-50 HYDROCHLOROTHIAZIDE; RESERPINE RESERPINE, HYDRALAZINE HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; ANDHYDROCHLOROTHIAZIDE RESERPINE RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; HYDRALAZINE HYDROCHLORIDE RESERPINE SER-A-GEN HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE SER-AP-ES HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE SERPASIL-ESIDRIX #1 HYDROCHLOROTHIAZIDE; RESERPINE SERPASIL-ESIDRIX #2 HYDROCHLOROTHIAZIDE; RESERPINE SPIRONOLACTONE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; SPIRONOLACTONE TEKTURNA HCT ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE TELMISARTAN AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; TELMISARTAN TELMISARTAN; HYDROCHLOROTHIAZIDE TELMISARTAN; HYDROCHLOROTHIAZIDE TEVETEN HCT EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE TIMOLIDE 10-25 HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE TRANDATE HCT HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE TRIAMTERENE AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; TRIAMTERENE TRIBENZOR AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL UNIPRES HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE UNIRETIC HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE VALSARTAN AND HYDROCHLOROTHIAZIDE HYDROCHLOROTHIAZIDE; VALSARTAN VALSARTAN; HYDROCHLOROTHIAZIDE VALSARTAN; HYDROCHLOROTHIAZIDE VASERETIC ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE VISKAZIDE HYDROCHLOROTHIAZIDE; PINDOLOL ZESTORETIC HYDROCHLOROTHIAZIDE; LISINOPRIL ZIAC BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE ZIDE HYDROCHLOROTHIAZIDE Supplemental Digital Content. HCTZ: 123 combination medications. Available at: http://www.accessdata.fda.gov/ Accessed October 29, 2015. .
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • Federal Register/Vol. 74, No. 27/Wednesday, February 11, 2009
    6896 Federal Register / Vol. 74, No. 27 / Wednesday, February 11, 2009 / Notices more accurately describe the prominently and conspicuously bear the approximately 1,000 reprocessed SUDs. information collection content. name of the manufacturer, the Each response is anticipated to take 0.1 Section 2(c) of The Medical Device manufacturer who reprocesses the SUD hours resulting in a total burden to User Fee Stabilization Act of 2005 for reuse, may identify itself using a industry of 100 hours. (Public Law 109–43) amends section detachable label that is intended to be In the Federal Register of November 502(u) of the act by limiting the affixed to the patient record. 17, 2008 (73 FR 67873), FDA published provision to reprocessed single-use The requirements of section 502(u) of a 60-day notice requesting public devices (SUDs) and the manufacturers the act impose a minimal burden on comment on the information collection who reprocess them. Under the industry. This section of the act only provisions. The agency received one amended provision, if the original SUD requires the manufacturer, packer, or comment in support of the collection of or an attachment to it prominently and distributor of a device to include their information stating that it is necessary conspicuously bears the name of the name and address on the labeling of a to help reprocessors of SUDs comply manufacturer, then the reprocessor of device. This information is readily with section 502(u) of the act. The the SUD is required to identify itself by available to the establishment and easily comment further stated that the name, abbreviation, or symbol, in a supplied.
    [Show full text]
  • Tryptophan Derivatives INDOL ALKALOIDS -Secale Cornutum
    Tryptophan Derivatives INDOL ALKALOIDS -Secale Cornutum -Faba calabarica -Semen Strychni -Gelsemium nitidum -Radix Rauwolfiae -Cortex Yohimbae -Aspidiospermae -Herba Catharanthi -Herba Vincae -Cortex Chinconae -Harman Alkaloids(-carboline) -Semen Pegani Radix Rauwolfia Rauwolfia serpentina (Apocynaceae) Radix must contain at least 0.15% reserpine- resinnamine group alkaloids. Rauwolf (German Botanist)16th century Rauwolfia serpentina; Used against snake bites and psyclological problems in India. Powdered roots, extract and purified alkaloids are used to control hypertension. Approximately 50 alkaloids are isolated from 25 Rauwolfia species. These alkaloids shows their activity by stimulating the release of serotonin and catecholamines so that sedative and tranquilizer activity occur. Reserpine; Reserpine absolutely lowers the blood pressure. Decreases pulse number with some euphory. Should be used in schizophrenia. Reserpine is a drug that is used for the treatment of high blood pressure, usually in combination with a thiazide diuretic or vasodilator. Large clinical trials have shown that combined treatment with reserpine plus a thiazide diuretic reduces mortality of people with hypertension. Resinnamine; Genetic hypertension (middle level) Deserpidine; 11-demethoxy reserpine (used like reserpine) Deserpidine and reserpine are used with diuretics against hypertension. Reserpine; white/pale yellow, odorless, crystal powder. Sensitive to light (darkens slowly). Commercial reserpine sources: R. serpentina (reserpine + resinnamine) R. micrantha (reserpine + resinnamine) R. tetraphylla (reserpine + deserpidine) R. vomitoria (reserpine) Mostly used species. Reserpine could be used synthetically but not efficient. Preference is natural sources. The Rauwolfia alkaloids reserpine and deserpidine, two alkaloids from Rauwolfia species, have been widely used for their antihypertensive action. Deserpidine is a compound with limited availability from natural sources, and its synthesis from 1 in six steps (41% overall yield) is reported in literature.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Table of Antihypertensive Drugs
    Chapter 14 Table of Antihypertensive Drugs F. GROSS and J. B. LUTH The following tables give information about the most important drugs used today in the treatment of high blood pressure. These lists do not in any way aim for completeness, in particular with respect to brand names, which are much more numerous for several of the mentioned products. The usual forms of adminis­ tration and average dosages are included, but various other schemes are also recommended for some drugs in some countries. What is said for the single entities with respect to completeness holds true even more for the fixed combinations, of which only a fraction of those marketed in a number or'countries has been included. Some examples of the combinations that make sense to the authors have been mentioned; many have been omitted; however, deletion does not mean in all cases - but it does in some - that the combi­ nation is considered useless. If a barbiturate is added to reserpine and a diuretic, it is difficult to ascribe to the new combination an improved effect on the high blood pressure. Quite a few more examples could be given, where the addition of a further ingredient to the basic combination of reserpine and a diuretic is nothing but the mixing in of a special flavor, and not of an antihypertensive component. Some of the readers may also feel that too many drugs and combinations have been listed, and they may never have heard the names of quite a few of them. Despite the incompleteness of the list, it gives an impression of the huge variety of pre­ parations, which will further increase with the growing number of /J-adrenergic blockers and their combinations with other drugs.
    [Show full text]